Introduction
Human immunodeficiency virus (HIV), the cause of acquired immunodeficiency syndrome (AIDS), has been a major global public health issue for decades. Approximately 35.0 million people were infected with HIV at the end of 2013 globally (http://www.who.int/ mediacentre/factsheets/fs360/en/). Although aggressive treatment regimens using highly active antiretroviral therapy (HAART) is successful in suppressing HIV viral replication and the progression of HIV disease, the persistence of virus within latently infected cells enables viral rebound to occur once antiretroviral treatment is terminated (Chun et al., 1995) . The association of many of the currently available antiretroviral agents with adverse side-effects dictates the need for continuing efforts to identify other antiretroviral targets and therapies.
Interferon (IFN), a key component of human innate immunity against invading pathogens acts by inducing expression of hundreds of IFN-stimulated genes (ISGs). Several HIV-1 restriction factors such as APOBEC3G, BST-2 and SAMHD1 can be stimulated by IFN (Malim and Bieniasz, 2012) but none of them account for the strong IFNmediated suppression of HIV-1. Recently, human myxovirusresistance protein B (MxB) has been identified as a major inhibitor of HIV-1 replication induced by IFN (Kane et al., 2013 , Goujon et al., 2013 , Liu et al., 2013 .
Like most mammals, humans carry two myxovirus resistance genes, MX1 and MX2, which have arisen by gene duplication (Horisberger et al., 1983 , Aebi et al., 1989 and encode the interferon-inducible dynamin-like GTPases MxA and MxB (Aebi et al., 1989) . Human MxA has been shown to suppress a wide range of pathogenic DNA and RNA viruses (Gordien et al., 2001) . In contrast, human MxB does not suppress the viruses tested in previous studies (Melen et al. 1996) . MxB inhibits HIV-1 replication at post-entry steps , Fackler and Keppler, 2013 , Liu et al., 2013 , Kane et al., 2013 , Goujon et al., 2013 , Goujon et al., 2015 , Goujon et al., 2014 . MxB binding to HIV-1 capsid (CA) has been shown to be important for viral restriction (Fribourgh et al., 2014 , Fricke et al., 2014 , Kong et al., 2014 .
Unlike APOBEC3, BST-2 and SAMHD1, MxB have not been found to be antagonized by HIV or SIV encoded regulatory proteins. Whether MxB antiviral activity plays an important role in vivo and whether HIV-1 can develop mechanisms to escape MxB activity during viral transmission has not been well characterized. In the present study, we identified a number of capsid variants that render the virus resistant to the activity of MxB. These MxB resistant capsid variants do not alter viral fitness and can still be recognized by MxB. Some of the identified variants are most commonly found in subtype C HIV-1 and are accumulating during expansion of the subtype C epidemic.
Materials and Methods

Ethics Statement
Whole blood was obtained from healthy donors that signed an informed consent. This study has been approved by the Ethics Committee of Institute of Virology and AIDS Research, First Hospital of Jilin University.
Plasmid Construction
The HIV-1-based expression vector pSCRPSY-MxB was a generous gift from Dr. Paul D. Bieniasz (The Rockefeller University). The MxB expression plasmid Retro-X-MxB and shRNA (TRCN0000056713) targeting MxB were generous gifts from Dr. Chen Liang (McGill University). To generate an expression vector encoding HA-tagged MxB fusion protein, the MxB-HA fragment was PCR amplified using Retro-X-MxB as the template, it was then digested with SalI and XbaI and cloned into VR1012 to generate pVR1012-MxB-HA. Plasmids were generated encoding MxB with an N-terminal truncation: MxB(Δ1-82). This truncated protein was fused with HIV-1 core binding motif sequences derived from PDZD8(MxB(Δ1-82)-sPDZD8), which was constructed by Generay Biotech (Shanghai). The HIV-1 GFP reporting vector (pNL4-3-ΔEnv-EGFP, Cat# 11,100) provided by Dr. Robert Siliciano (Johns Hopkins University) was obtained through the NIH AIDS Research and Reference Reagent Program, NIH. HIV-1 NL4-3 ΔEnv-GFP with capsid mutants was provided by Dr. Christopher Aiken (Vanderbilt University School of Medicine). The NL4-3 CA G116A infectious clone was generated by replacing the BssHII-SpeI DNA fragment from NL4-3 (Cat#114, provided by Dr. Malcolm Martin and obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH) with that from NL4-3 ΔEnv-GFP (G116A). The composition of the NL4-3 CA G116A construct was confirmed by DNA sequencing.
Cells
HEK293T cells (AIDS Research and Reference Reagents Program, Cat #3522) and TZM-bl cells (AIDS Research and Reference Reagents Program, Cat#8129) were maintained in Dulbecco's modified Eagle's medium (DMEM, Life Technology) with 10% fetal bovine serum (FBS) and penicillin-streptomycin. The cell lines U937 and K562 (ATCC) were provided by Dr. Donald Small (Johns Hopkins University) and cultured in RPMI medium with 10% FBS. SupT1 cells were grown in RPMI medium supplemented with 10%FBS. Peripheral blood mononuclear cells (PBMC) were obtained from buffy-coat by Ficoll density gradient centrifugation. Monocytes enriched from PBMC by positive selection using CD14 MicroBeads were differentiated into macrophages by culturing in RPMI supplemented with 10% FBS, 50 ng/ml human GM-CSF (R&D Systems) 100 U/ml penicillin, and 100 μg/ml streptomycin. shRNAsilenced cell lines were generated according to the manufacturer's instructions (Open biosystem) and selected for resistance to puromycin. All cultured cell lines were maintained at 37°C in a humidified atmosphere containing 5% CO 2 .
Transfection and Immunoblotting
DNA transfection was carried out using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. HEK293T cells were harvested at 48 h after transfection, washed twice with cold PBS, and lysed in lysis buffer (150 mM Tris, pH 7.5, with 150 mM NaCl, 1% Triton X-100, and complete protease inhibitor cocktail tablets [Roche] ) at 4°C for 30 min, then centrifuged at 10,000g for 30 min. The materials were then analyzed by SDS-PAGE and immunoblotting with the appropriate antibodies as previously described (Wei et al., 2012) . The following antibodies were used: anti-MxB (Novus Biologicals, NBP1-81018), anti-Cyclophilin A (Santa Cruz Biotechology, sc-134,310), anti-HA (Covance, MMS-101R-1000), and anti-β-actin MAb (Sigma, A3853). Monoclonal antibody anti-CAp24 (Cat #1513) was obtained from the AIDS Research and Reference Reagents Program.
Viruses and Infection
For HIV-1 GFP viral production, HEK293T cells were transfected with 9 μg of HIV-1ΔENV-GFP and 3 μg of pCMV-VSV-G encoding plasmids; for shRNA production, HEK293T cells were transfected with 5 μg of the shRNA construct, 5 μg of the packaging plasmid pΔ8.91, and 2 μg of the VSV-G encoding plasmid. Medium was harvested 48 h later, then filtered at 0.45 μm. Supernatants were then purified, and lentivirus was concentrated by ultracentrifigation at 28 K for 1.5 h with a 20% sucrose cushion. The virus pellet was then dissolved in PBS and stored at −80°C. For single infections with the HIV-1-GFP virus, U937, K562, or 293T cells were plated in 24-well plates 12 h before infection, and the efficiency of productive infection was analyzed 48 h later by flow cytometry (FACSCalibur, BD Biosciences). For Transmitted/founder (T/F) of HIV-1 (ZM249M) infection, viruses were generated from transfected HEK293T cells. SupT1 or MxB-SupT1 cells were exposed to equal amount of ZM249M HIV-1 for 2 h and the supernatants were replaced by fresh media. Two days later, the amount of virus that was released into the culture supernatant was determined by infecting the TZM-bl indicator cells. All results are representative of more than three independent experiments.
Viral Replication Assay
Primary PBMC were separated from whole blood of healthy donors using the Ficoll-Hypaque method. CD4 + cells were isolated using CD4
MicroBeads (Miltenyi, Bergisch Gladbach, Germany). Cells were then cultured in RPMI 1640 medium containing 5 μg/ml PHA and 20 IU/ml human recombinant IL2 for 3 days. HIV-1 NL4-3 and NL4-3 CA G116A viruses were generated by transfecting HEK293T cells. Virus stocks were assessed for CAp24 concentration using an HIV-1 p24 ELISA Assay kit (XpressBio, Frederick, MD). Equal amounts of virus were used to infect activated T cells and infected cells were washed 6 h after infection. Quantitation of newly produced virus in the supernatants of infected cultures was determined by CAp24 ELISA and a viral infectivity assay using TZM-bl cells. Viruses in the supernatants were harvested at 2, 4, and 8 days post infection and determined using the CAp24 ELISA assay. The infectivity of newly produced viruses was assessed by using the same volume of supernatants to infect the indicator TZM-bl cells. Briefly, 2 × 10 4 TZM-bl cells were placed in 96-well culture plates and cultured overnight. The cells were infected with 50 μl supernatants containing NL4-3 or NL4-3 CA G116A viruses. After 48 h incubation at 37°C with 5% CO 2 , luciferase activity in cell lysates was measured using the Luciferase Assay kit (Promega, Madison, WI).
Quantitative Real-time PCR
Cells were collected at 24 h post-infection and washed with PBS. Total RNA was extracted from cells by TRIzol (Invitrogen) and cDNA samples were generated by using the High Capacity cDNA Reverse Transcription Kit (Invitrogen) according to the manufacturer's instruction. Samples were then analyzed by quantitative PCR using FastStart Universal SYBR Green Master Mix (Roche) and the ABI 7000 sequence detection system (Applied Biosystems). The sequences of DNA primers for real-time PCR are as follows: Human IFN-β, sense: AGGACAGGATGA ACTTTGAC, anti-sense: TGATAGACATTAGCCAGGAG; Human GAPDH, sense: ATGACATCAAGAAGGTGGTG, anti-sense: CATACCAGGAAATGAG CTTG.
Step Gradient Analyses
For step sucrose gradient analysis, 2 × 10 6 MxB-K562 cells were harvested and resuspended in lysis buffer (10 mM Tris, pH 7.4, 1.5 mM MgCl 2 , 10 mM KCl, and 0.5 mM DTT). Cells were frozen and thawed twice. Cell lysates were centrifuged at 11,000g for 10 min. The supernatant was collected and immediately used in the binding assay. Purified virus was dissolved in PBS buffer, exposed briefly to 0.1% Triton X-100, and loaded onto soluble MxB containing cell lysates and step sucrose gradient as previously described (Shah and Aiken, 2011) . Three fractions were harvested: one containing soluble proteins (F1), a buffer fraction (F2), and the virus-core containing fraction (F3). The individual gradient fractions were then subjected to immunoblot analysis.
Statistical Analysis
Differences among test groups were analyzed by an ANOVA test (Stata Corp, College Station, TX). A value of p b 0.05 was considered to be significant.
Results
Naturally Occurring Capsid Variants That Do Not Reduce Viral Fitness Render HIV-1 Resistant to the Inhibition of MxB
We screened a number of CA variants with single amino acid substitutions that have been shown to decrease (P38A, Q63A/Q67A) or increase (E45A) HIV-1 core stability or to alter host factor binding (G89V) to the HIV-1 core (Shah et al., 2013 , Forshey et al., 2002 . We observed that certain CA mutations could indeed make mutant HIV-1 resistant to MxB mediated inhibition (Fig. 1) . These HIV-1 variants can be separated into three classes: (1) resistant to MxB but with reduced viral infectivity (P38A, Q63A/Q67A) ( Fig. 1a-d) ; (2) resistant to MxB with normal infectivity but enhanced ability to trigger interferon production (CA-G89V) ( Fig. S1 and Fig. 1h) ; and (3) resistant to MxB with normal infectivity and unaltered ability to trigger interferon production at a level similar to that seen with WT HIV-1 (Fig. 1e-h) .
Interestingly, we identified three CA surface mutants (H87P, G116A, P207A) that could significantly restore viral infection levels even in the presence of MxB expression (Fig. 1f) . By investigating the effects of these capsid mutants on the HIV-1 life cycle, we confirmed that these capsid mutants maintained similar viral infectivity as wild type HIV-1 (Fig. 1g) . cDNA encoding capsid generated during reverse transcription of viral RNA can potentially interact with host cell proteins and trigger an IFN response that inhibits viral replication. For example, the cDNA encoding the G89V capsid mutant does not binds host CypA resulting in immune activation that prevents viral replication. The CA mutants we have generated did not trigger such immune activation in primary monocyte-derived macrophages (Fig. 1h) .
To investigate the infectivity of HIV-1 viruses containing these MxBresistance CA mutations in interferon (IFN)-treated primary macrophages, we isolated macrophages from healthy donors as previously described (Yu et al., 1991) . IFN pre-treated and untreated cells were challenged with equal amounts of the indicated GFP-reporter viruses. 48 h after infection, GFP positive cells were analyzed using flow cytometry. HIV-1 mutants (H87P, G116A, P207A) maintained similar infectivity to wild-type virus in primary macrophages (Fig. 2a) . As expected, interferon treatment significantly increased MxB expression in primary macrophages (Fig. 2b) . More importantly, these MxB resistant viruses (H87P, G116A, P207A) became more resistant (2.64-3.40 fold) to interferon-mediated anti-viral activity than the wild-type HIV-1 virus in primary macrophages (Fig. 2a) .
Transmitted/founder (T/F) of HIV-1 subtype C ZM249M containing the G116A mutation was also evaluated for MxB sensitivity. Similar infectivity was detected for NL4-3 and ZM249M viruses in K562 cells (Fig. 2c) . Compared to NL4-3 virus, ZM249M virus was more resistant to MxB-mediated viral inhibition in MxB transduced SupT1 cells (Fig. 2c) . In addition, the virus replication assay confirmed that HIV-1 NL4-3 CA G116A maintained a replication capacity similar to the parental NL4-3 virus in primary T cells (Fig.S1 ). Together, these data indicate that the G116A mutation in CA can reduce HIV-1 sensitivity to MxB restriction.
MXB Resistant Capsid Variations Are Detected Among Primary HIV-1 Isolates
HIV-1 variants (H87P, G116A, P207A) were less sensitive to MxB and still maintained viral infectivity. More importantly, these HIV-1 variants carrying MxB-resistance mutations could be detected among primary HIV-1 isolates from different subtypes. For example, the 2013 HIV sequence compendium reveals that A116 variants are detected among subtypes A, C, and D, which are prevalent in Africa and Asia as well subtype B which is the prevalent strain in Europe and North America. In fact, in subtype C, the A116 variant is the dominant genotype (Fig. 3a) . The accumulation of P87 and A207 variants among HIV-1 subtypes A, B, C and D was also detected but less prevalent than A116 (Fig. S2) .
To further evaluate the accumulation of MxB-resistance mutations during HIV-1 transmission in human populations, we analyzed the sequences of circulating HIV-1 stains collected in China since the beginning of the epidemic (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) . A unique subtype B/C recombinant (CRF08) was generated in Yunnan Province (McClutchan et al., 2002 , Yu et al., 1998 , Piyasirisilp et al., 2000 . This recombinant arose from HIV-1 subtype B from Myanmar and subtype C from India in association with drug trafficking patterns between those two countries . The majority of the gag gene of CRF08 is subtype C but contains a fragment of CA gene from subtype B (Fig. S3) . CRF08 was then transmitted to the neighboring Guangxi Province from Yunnan Province in 1997. The Guangxi founder CRF08 viruses in 1997 all carried the G116 genotype (Fig. 3b) . However, 55% of the circulating CRF08-BC strains detected in 2010 carried the A116 genotype and the G116 viral strains decreased to 40% (Fig. 3b) .
Accumulation of MxB resistance mutations at position 207 of CA during HIV-1 transmission in Southern China was observed (Fig. S4) . While the parental subtypes B, C and original CRF08 BC recombinant HIV-1 strains all contained the MxB-sensitive P207 genotype, more recent CRF08 BC recombinant HIV-1 strains carried the A207 MxBresistant genotype (Fig. S4 ). Similar accumulation of CA mutation at position 208, which was identified in a recent report (Liu et al., 2015) , was also observed (Fig. S5 ). These findings all suggest possible selection for MxB resistant HIV-1 variants. 
Capsid Variants Render HIV-1 Resistant to the Inhibiton of MxB Without Affecting Capsid Binding
MxB has been shown to recognize HIV-1 capsid and this interaction is important for MxB-mediated HIV-1 inhibition (Fribourgh et al., 2014 , Kong et al., 2014 , Fricke et al., 2014 . Surprisingly, amino acid variations at positions 87, 116 and 207 of CA influenced the sensitivity of these mutant HIV-1 to MxB activity but did not enhance the interaction of the mutant core with MxB (Fig. 4) . We next used a different CA-MxB binding assay recently reported by others to investigate the interaction between CAp24 (WT and mutants) and MxB (Liu et al., 2015) . All tested CAp24 variants maintained MxB binding (Fig.S6) . Deletion of the amino-terminal region of MxB (MxBΔ1-82) resulted in reduced HIV-1 core binding and impaired ability to inhibit HIV-1 (Fig. S7A-C) . Addition of a CA binding motif from PDZD8 (Guth and Sodroski, 2014, Henning et al., 2010) restored HIV-1 core binding but could not enhance the anti-HIV activity of chimeric MxB (Δ 1-82)-PDZD8 (Fig. S7B, C) . HIV-1 CA mutants lacking CypA interaction became resistant to MxB restriction (Liu et al., 2013 , Kane et al., 2013 , Goujon et al., 2013 , Busnadiego et al., 2014 but these mutations had no effect on MxB binding (Liu et al., 2015 , Fricke et al., 2014 . CsA treatment which disrupts CyPA and CA interaction also impaired MxB mediated HIV-1 inhibition (Fig. S8) .
HIV-2 is less sensitive to MxB mediated restriction (Fricke et al., 2014 , Goujon et al., 2013 and its CA is known to interact poorly with CypA (Lahaye et al., 2013) . Interestingly, enhancement of CypA binding to HIV-2 CA (Lahaye et al., 2013) (Fig. S9A, B) did not increase HIV-2 sensitivity to MxB mediated restriction (Fig. S9C) . These data again suggest that MxB binding to HIV-1 CA is necessary but not sufficient for MxB-mediated restriction.
It has been reported that U937 cells express significant level of endogenous MxB proteins but do not suppress HIV-1 infection even in the presence of interferon (Kane et al., 2013) . We have observed that interferon treatment could significantly enhance MxB expression in Jurkat cells (Fig. S10B) . However, enhanced MxB expression had little effect on HIV-1 infection when compared to untreated Jurkat cells (Fig. S10A) . The cell type dependent differences in HIV-1 sensitivity to MxB suggest the potential existence of a co-factor required for MxB mediated HIV-1 restriction.
Discussion
Interferon (IFN) is a key component of the innate immune response to exogenous pathogens. Interferon increases the mRNA levels of interferon-stimulated genes (ISGs) in vivo which is thought to account for its antiviral activity. Recent studies have identified that human myxovirus resistance protein B, one of the ISG's, contributes to the inhibition of HIV-1 replication by interferon. However, whether HIV-1 could evolve to counteract against MxB restriction has been undefined. In the present study, we identified and characterized a number of capsid variants that render the mutant HIV-1 viruses resistant to the inhibition of MxB without altering viral fitness. These mutant viruses maintained viral infectivity that is comparable to the wild-type virus in human cell lines as well as in primary macrophages (Fig. 1) . Furthermore, like wildtype virus, they do not trigger type I interferon production during infection of primary macrophages (Fig. 1h) . This is in sharp contrast to the HIV-1 mutant (G89V) that lost the ability to bind CyPA and became resistant to MxB inhibition but could not prevent interferon production (Fig. 1h) .
The capsid mutations that could render HIV-1 less sensitive to MxB restriction are detected among primary HIV-1 isolates. Of particular interest is the finding that MxB resistant variants containing A116 are most commonly found in the Clade C HIV-1 viruses that are the most rapidly expanding clade throughout the world. Furthermore, as the HIV-1 epidemic spreads in China, there is a clear positive selection for those MxB resistance variants that do not alter viral fitness. These findings support a critical role for MxB as a selective force during HIV-1 transmission and evolution. It is not clear why the A116 mutation that has become predominant in subtype C HIV-1 viruses has not attained the same dominance in other HIV-1 subtypes such as A, B, and D, which still primarily carry G116. One possibility is that these HIV-1 subtypes do not encounter MxB inhibition during HIV-1 transmission when compared to subtype C HIV-1. Alternatively, A116 in CA is less fit than G116 in certain HIV-1 subtypes and is only selected when they encounter MXB selection. Another possibility is that HIV-1 subtypes A, B, and D use other strategies to overcome MxB restriction.
MxB targets HIV-1 capsid to mediate its anti-viral function. We have observed that HIV-1 resistant variants maintained the ability to be recognized by MxB, suggesting the existence of MxB co-factor(s) required for MxB mediated viral restriction. Consistent with this idea, Jurkat cells express high level of endogenous MxB proteins after interferon treatment (Fig. S10) . However, interferon induced MxB expression did not alter HIV-1 infectivity in these Jurkat cells compared to the untreated Jurkat cells (Fig. S10) . It has been reported that U937 cells express MxB, but this expression has limited impact on HIV-1 infection (Kane et al., 2013) . CypA has been reported to be a critical factor for MxB mediated HIV-1 restriction. We have observed that addition of CypA binding to HIV-2 capsid did not alter HIV-2 sensitivity to MxB (Fig. S9 ). Factor(s) in addition to CypA may be required for MxB mediated HIV-1 restriction. Interestingly, the three MxB-resistant HIV-1 capsid variants are all located on the raised surface region formed by two subunits of the capsid hexamer (Fig. S11) , suggesting that these sites could influence the putative MxB cofactor binding but may not alter intrinsic features of the viral core (Fig. 5) . Identification of the critical role of these HIV-1 capsid mutations in overcoming a host restriction factor may provide opportunities for the development of therapeutic interventions.
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